

FIGURE S1. Plot of predicted scores on the 24-item Hamilton Depression Rating Scale by treatment group over time (using different slopes from baseline to week 4 and then from week 4 to week 16)

Citalopram=CIT; Methylphenidate=MPH; Placebo=PBO




TABLE S1. Estimated effect sizes

Variable	CIT+PBO (N=48)	MPH+PBO (N=48)	CIT+MPH (N=47)
<i>Psychiatric Symptoms</i>			
HAM-D*	-2.93	-2.23	-3.35
Montgomery-Åsberg Depression Rating Scale	-2.44	-1.62	-2.64
Apathy Evaluation Scale	0.98	0.75	0.95
<i>Health-related quality of life</i>			
Short Form 36-Item Health Survey			
Energy	0.78	0.81	1.09
Well-being	1.50	0.81	1.57
Role-emotional	0.93	0.84	1.40

Note: *HAM-D=24-item Hamilton Depression Rating Scale

Citalopram=CIT; Methylphenidate=MPH; Placebo=PBO

TABLE S2. Adverse effects profile

	Citalopram + Placebo		Methylphenidate + Placebo		Citalopram + Methylphenidate	
	N	%	N	%	N	%
No. randomized	48		47		48	
No. with adverse event data	44		42		40	
No. serious adverse events	1		0		0	
Adverse events collected (%)						
Concentration difficulties	0		5	11.9	3	7.5
Asthenia	0		1	2.4	4	10.0
Sedation	6	13.6	1	2.4	3	7.5
Failing memory	3	6.8	3	7.1	3	7.5
Depression	1	2.3	1	2.4	1	2.5
Tension	6	13.6	7	1.7	2	13.3
Increased duration of sleep	4	9.1	4	9.5	1	2.5
Decreased duration of sleep	9	20.5	10	23.8	7	17.5
Increased dream activity	1	2.3	2	4.8	0	
Akinesia	0		1	2.4	0	
Tremor	0		1	2.4	3	7.5
Akathisia	0		1	2.4	0	
Paraesthesias	0		2	4.8	0	
Increased salivation	0		1	2.4	1	2.5
Reduced salivation	3	6.8	4	9.5	9	22.5
Nausea	9	20.5	8	19.0	13	32.5
Diarrhea	5	11.4	4	9.5	4	10.0
Constipation	4	9.1	0		4	10.0
Polyuria	1	2.3	3	7.1	4	10.0
Orthostatic dizziness	2	4.5	1	2.4	3	7.5
Palpitations	0		2	4.8	1	2.5
Increased perspiration	1	2.3	3	7.1	1	2.5
Rash – general	2	4.5	2	4.8	1	2.5
Rash – psoriatic	0		1	2.4	1	2.5
Rash – cannot be classified	2	4.5	1	2.4	0	
Increased pigmentation	1	2.3	0		0	
Weight gain	4	9.1	0		0	
Weight loss	1	2.3	1	2.4	1	2.5
Diminished sexual desire	1	2.3	2	4.8	2	5.0
Erectile dysfunction	0		1	2.4	0	
Ejaculatory dysfunction	0		0		1	2.5
Orgastic dysfunction	0		1	2.4	1	2.5
Dry vagina	1	2.3	0		0	
Headache – migraine	6	13.6	2	4.8	3	7.5
Headache – tension	2	4.5	0		0	

Note: None of the group comparisons were statistically significant.